Bioventus LLC, a biologics company formed in May 2012 as an offshoot of Smith & Nephew, the global medical technology business, is launching its products in Italy. This month the division of the Smith & Nephew biologics and clinical therapies business in Italy, including employees and products, will transition over to Bioventus.
Bioventus to Market Products in Italy
1 min read Premium comments
Secondary
“With the Bioventus launch, our Italian customers will notice an increase in the level of support and product expertise available to them through our new multi-lingual customer care center that opened last month in our Netherlands’ office, ” said Mark Augusti, CEO of Bioventus. “However, other than that, changes should be minor—our customers’ sales representatives will not change and our products will simply be rebranded.” Augusti explained that Bioventus products available in Italy will switch from their current Smith & Nephew labeling to Bioventus. The products themselves will not change.
Included in the Bioventus product line is EXOGEN Ultrasound Bone Healing System—a product which its manufacturers believe will accelerate the healing of recent fractures and heal bones that have either delayed healing or stopped healing completely. Company officials say that EXOGEN heals 86% of non-union fractures and accelerates the healing of fresh fractures up to 38%.
Another product is DUROLANE, a single-injection joint-fluid treatment designed to relieve osteoarthritis pain in synovial joints. DUROLANE was developed and is manufactured by Q-Med and marketed by Bioventus. Both products are distributed world-wide. Bioventus is headquartered in Durham, North Carolina.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.